Biometrix Technology Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
2
Ending by 2030
Dec 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 6, 2026The maintenance fee for Benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent comprising the same (US 11,667,661) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
- 1 fee due Apr 22, 2027The maintenance fee for Method of designing DNA probe chip for room temperature hybridization and the DNA probe chip (US 10,450,600) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,013,188 | Iminecalixarene derivatives and aminocalixarene derivatives, method of preparation thereof, and self-assembled monolayer prepared by the method, fixing method of oligo-DNA by using the self-assembled monolayer, and oligo-DNA chip prepared by the method In force · From the USPTO record | In force | From the USPTO record | |
| US 10,450,600 | Method of designing DNA probe chip for room temperature hybridization and the DNA probe chip In force · From the USPTO record | In force | From the USPTO record | |
| US 8,288,443 | Modified glass fiber with monolayer of aminocalixarene derivatives and iminecalixarene derivatives In force · From the USPTO record | In force | From the USPTO record | |
| US 11,667,661 | Benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent comprising the same In force · From the USPTO record | In force | From the USPTO record | |
| US 11,998,530 | Micelle comprising benzimidazole-carbohydrate conjugate compound, preparation method thereof and use thereof as anticancer agent or antiviral agent comprising the same In force · From the USPTO record | In force | From the USPTO record | |
| US 12,043,644 | Benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent or anti-virus agent comprising the same In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 6: 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 no status recorded